Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Executives from
Heptares Therapeutics
and
Oxygen Healthcare
(O2h) announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.
Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”
Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”
Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”
Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”
